Neurocrine Biosciences Reports Third Quarter 2021 Financial

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2021. "Our third...

Related Keywords

Japan , United States , Neurocrine Biosciences , Neurocrine Bioscience , Kevin Gorman , Neurocrine Biosciences Inc , Linkedin , European Union , Takeda Pharmaceutical Company Limited , Ministry Of Health , Mitsubishi Tanabe Pharma Corporation Submitted Marketing Authorization , Nasdaq , Chief Executive Officer , Product Sales , Commercial Highlights , In Process Research , Key Activities , Top Line Data Expected , Cerebral Palsy , Neurological Indication , Registrational Study , Psychiatric Indication , Adrenal Hyperplasia , Impairment Associated , Major Depressive Disorder , Pediatric Epilepsy , Epileptic Encephalopathy , Continuous Spike , Wave During Sleep , Onset Seizure , Developmental Epileptic Encephalopathy , Webcast Today , Nc ,